Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

Last updated: December 3, 2019
Sponsor: Actavis Inc.
Overall Status: Completed

Phase

3

Condition

Stomach Discomfort

Hyponatremia

Colic

Treatment

N/A

Clinical Study ID

NCT02498418
ACTA/RIFX/2015
  • Ages > 18
  • All Genders

Study Summary

The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in participants with travelers' diarrhea.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult male or nonpregnant female aged ≥18 years non-indigenous travelers (for example;visiting students/faculty or international tourists) affected by naturally acquiredacute diarrhea. Diarrhea is defined as the passage of at least 3 unformed stools in a 24-hour period. Stools are classified as formed (retains shape), soft (assumes shapeof container), or watery (can be poured). When using this classification, both softand watery stools are unformed and abnormal.

  2. At least 3 unformed stools recorded within the 24 hours immediately precedingrandomization.

  3. At least 1 of the following signs and symptoms of enteric infection:

  • abdominal pain or cramps

  • nausea

  • vomiting

  • fecal urgency

  • excessive gas/flatulence

  • tenesmus

  1. Women of child-bearing potential have a negative pregnancy test prior to beginningtherapy and agree to use effective contraceptive methods during the study.

Exclusion

Exclusion Criteria:

  1. Pregnant, breast feeding, or planning a pregnancy.

  2. Immediately prior to randomization, acute diarrhea for >72 hours.

  3. Presence of:

  • fever (≥100 degrees fahrenheit [°F] or ≥37.8 degrees celsius [°C]), or

  • hematochezia (blood in stool), or

  • clinical findings suggesting moderate or severe dehydration.

  1. Active, uncontrolled, or clinically significant diseases or disorders of the heart,lung, kidney, gastrointestinal (GI) tract (other than infectious diarrhea intravelers), or central nervous system.

  2. Administration of any of the following:

  • any antimicrobial agents with an expected activity against enteric bacterialpathogens within 7 days preceding randomization

  • more than 2 doses of a symptomatic antidiarrheal compound such as antimotilityagents, absorbent agents, and antisecretory agents within 8 hours precedingrandomization

  1. Use of any drug such as aspirin or ibuprofen (Advil), which can cause GI bleeding.Acetaminophen (Tylenol) or paracetamol is acceptable.

Study Design

Total Participants: 739
Study Start date:
January 06, 2016
Estimated Completion Date:
February 28, 2017

Study Description

This is a randomized, placebo-controlled bioequivalent study with a clinical endpoint in the treatment of travelers' diarrhea. After 3 unformed stools are recorded within the 24 hours immediately preceding randomization, participants are to be randomized to receive the generic rifaximin 200 mg oral tablet, Xifaxan (the reference listed drug)200 mg oral tablet, or placebo 3 times daily for 3 days (that is; on Days 1, 2, and 3).

Connect with a study center

  • Site 1

    Coral Gables, Florida 33134
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.